VANCOUVER, Feb. 14 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), a global
specialty pharmaceutical and medical device company, today
announced unaudited interim and annual consolidated financial
results for the fourth quarter and year ended December 31, 2007.
The unaudited financial results are subject to further review and
potential adjustment as described under the section "Financial
Information". "Throughout 2007, we continued to build our business
with the launch of new products, the receipt of regulatory
approvals, and the establishment of new partnerships. We expect our
new product pipeline and our portfolio of innovative currently
marketed products to provide growth and opportunity in 2008 and
beyond," said Dr. William Hunter, President and CEO of Angiotech.
"With our expanded sales and marketing team in place and many of
our reorganization activities completed, we believe that we are
well positioned to achieve our targets for sales growth and gross
margin improvements in the coming year," said Tom Bailey, Chief
Financial Officer of Angiotech. "We are confident that during 2008
we will begin to realize returns on the various investments we have
made in our business over the last two years." Fourth Quarter
Financial Highlights - Total revenue, as adjusted for non-recurring
items, was $70.7 million. Total revenue under generally accepted
accounting principles (GAAP) was $71.4 million. - Net product
sales, as adjusted, were $43.5 million, and were derived primarily
from sales of our various single use specialty medical devices as
well as from sales of medical device components to third parties.
Net product sales under GAAP were $43.9 million. - Royalty revenue
was $27.2 million, and included $25.4 million of royalty revenue
derived from sales by Boston Scientific Corporation (BSC) of
paclitaxel-eluting coronary stent systems. The average blended
royalty rates indicated during the quarter were 7.5 percent for
U.S. sales, and 5.7 percent for sales recorded in other countries.
- Adjusted EBITDA (earnings before interest, taxes, depreciation
and amortization, adjusted to exclude certain non-cash and
non-recurring items) was $6.8 million. Excluding research and
development expenses, the significant majority of which are
discretionary and relate primarily to our Pharmaceutical
Technologies segment, adjusted EBITDA would be $20.2 million. -
GAAP net loss and net loss per share from continuing operations
were $16.8 million and $0.20, respectively. - Adjusted net loss
from continuing operations and adjusted net loss per share from
continuing operations (GAAP net loss as adjusted to exclude certain
non-cash and non-recurring items) were $7.5 million and $0.09,
respectively. - As of December 31, 2007, cash and long-term
investments were $115.8 million and net debt was $465.8 million.
Fourth Quarter Business Highlights - 5-FU Central Venous Catheter
("CVC"). In December 2007 we submitted a 510(k) application to the
U.S. Food and Drug Administration (FDA) to market and sell our 5-FU
CVC. We expect the clinical data from our recently completed 960
patient clinical trial, which evaluated the clinical performance of
our 5-FU CVC as compared to a market leading anti-infective CVC, to
be presented by the clinical investigators at the ISICEM 28th
International Symposium on Intensive Care and Emergency Medicine in
Brussels, Belgium on March 18, 2008. Should our 5-FU CVC product
candidate receive FDA marketing clearance, we would anticipate
commencing commercial launch activities in the second half of 2008.
- Quill(TM) SRS: In October 2007 we received CE Mark approval to
begin marketing the Quill(TM) Self-Retaining System (SRS)
MONODERM(TM) product line in Europe. In addition, we exceeded our
stated goal of 100 Quill(TM) SRS hospital accounts by the end of
2007, and expect to expand the number of Quill(TM) SRS SKUs
available for sale to our customers in 2008. - Vascular Wrap(TM):
Enrolment in our AV access human clinical trials in the U.S. and
Europe continues and we currently expect to complete enrolment in
these studies around the end of the first half of 2008. - Stem Cell
Therapies: In December 2007 our partner, Athersys, Inc. received
authorization from the U.S. FDA to begin a Phase I clinical trial
evaluating the safety of MultiStem(R) in the treatment of acute
myocardial infarction. We have an agreement with Athersys to co-
develop and commercialize MultiStem(R), Athersys' non-embryonic
stem cell platform technology, for use in the indications of acute
myocardial infarction and peripheral vascular disease. - TAXUS(R)
paclitaxel-eluting stent systems: In December 2007 our partner,
BSC, announced that the TAXUS(R) Liberte(TM) paclitaxel- eluting
coronary stent system received European CE Mark approval for use in
diabetic patients. 2008 Outlook Our financial outlook for the
upcoming fiscal year ending December 31, 2008 is presented below.
Several material factors and assumptions were used to derive our
2008 outlook, including: (i) estimates of medical procedure and
patient population growth rates for the various end markets
relating to our medical products business; (ii) estimates of the
impact of pricing changes, pricing strategies and competition with
respect to certain of our currently marketed medical products;
(iii) competitive analysis and estimates of relative market share
with respect to certain key product lines; (iv) estimates of
revenue growth and customer composition relating to our sales of
medical device components to other medical products companies; (v)
analysis of the impact of our manufacturing consolidation, product
sales mix and pricing on cost of goods sold; (vi) estimates of
selling, general and administrative expenses necessary to support
our revenue growth and overall business goals; and (vii) estimates
of research and clinical expenses necessary to support our various
new product development and research programs. The outlook
presented below contains estimates of certain expenses based on
non-GAAP measures, and are prepared consistent with our current and
previous presentations of our historical financial information.
Specifically, our outlook for research and clinical expenses, sales
and marketing expenses and general and administrative expenses
exclude estimates for stock based compensation expenses, for
certain non-recurring expenses expected to be incurred in the first
half of 2008 related to the completion of the consolidation of our
Syracuse, NY operations, and for certain litigation related
expenses. The estimates for these certain operating expenses are
inherently unpredictable or subject to significant fluctuation for
reasons unrelated to our business performance. The key elements of
our 2008 outlook are as follows: - Medical Products year over year
total revenue growth goal of 15% or greater, with higher growth
expected from several selected promoted brand product lines,
including Quill(TM) SRS, Skater(TM) drainage catheters, EnSnare(R)
vascular retrieval devices, and our BioPince(TM) biopsy needle
franchise, among others; - Improvements in gross margins as
compared to 2007, driven by a combination of expected improvements
in product sales mix and the expected completion of the
consolidation and closure of our operations in Syracuse, New York;
- Research and clinical expenses ranging from $45 to $50 million,
with expenses weighted to the first half of 2008, driven primarily
by continued clinical, manufacturing and pre-launch activities
related to our 5-FU CVC and Vascular Wrap(TM) product candidates; -
Sales and marketing expenses ranging from $50 to $60 million,
driven by the achievement of stated sales goals and the incurrence
of a full year of certain expenses related to the 2007 expansion of
our sales and marketing personnel; - General and administrative
expenses ranging from $40 to $45 million, reflecting continued
reductions in selected administrative expenses as compared to 2007;
and - Capital expenditures ranging from $12 to $15 million. Our
financial outlook is forward-looking information, and actual
results may be materially different from any results, events or
developments expressed or implied by our financial outlook. We
expect our financial results may vary from the outlook provided as
a result of several key factors, including the progress of our
various research, clinical development and product launch
initiatives, the achievement of selected sales growth targets and
the timing of product sales growth, the outcome of various ongoing
partnering, business development and financing discussions, and the
level of royalty revenues we receive from our partner BSC in future
periods and the impact such results may have on our election to
pursue certain discretionary aspects of our budgeted expenses in
2008. It is expected that, at the present time, we will have
adequate cash and liquidity resources to execute our various
research, product development and growth initiatives in 2008. Our
financial outlook is provided to give investors an assessment of
our expected financial results and our future business, and may not
be appropriate for any other purposes. Given the risks,
uncertainties and assumptions associated with such information,
readers are cautioned not to place undue reliance on our financial
outlook. Except as required by law, we disclaim any obligation to
update our financial outlook. Financial Information
--------------------- This press release contains the condensed
financial information derived from the preliminary unaudited
interim consolidated financial statements for the three month
periods ended December 31, 2007 and 2006, and preliminary unaudited
consolidated financial statements for the years ended December 31,
2007 and 2006 as previously reported. The unaudited financial
information presented should be considered preliminary and is
subject to potential adjustments, including, but not limited to,
potential adjustments to certain tax related items, pending the
conclusion of the 2007 year-end audit. Upon completion of the 2007
year-end audit process and the approval of our full year 2007
audited consolidated financial statements by our Board of
Directors, full audited consolidated financial statements and
Management's Discussion and Analysis for the three years ended
December 31, 2007, will be filed with the relevant regulatory
agencies, as well as posted on our website at
http://www.angiotech.com/. We completed the acquisition of the
operations of American Medical Instruments Holdings, Inc. ("AMI")
on March 23, 2006. Because of the timing of the AMI acquisition,
our operating results for the twelve month period ended December
31, 2006 include AMI's results of operations from the period of
March 24, 2006 to December 30, 2006, as compared to the current
twelve month period which reflects combined results for the full
year. As a result, our results for the twelve months ended December
31, 2007 do not reflect a comparable operating period as compared
to the nine months ended December 31, 2006. Amounts, unless
specified otherwise, are expressed in U.S. dollars. Financial
results are reported under GAAP unless otherwise noted. All per
share amounts are stated on a diluted basis unless otherwise noted.
Use of Certain Non GAAP Financial Measures
------------------------------------------ Certain financial
results presented in this press release include non-GAAP measures
that exclude certain items. Adjusted net loss from continuing
operations, adjusted net loss per share from continuing operations
and adjusted earnings before interest, taxes, depreciation and
amortization ("Adjusted EBITDA") exclude certain non-cash and
non-recurring items such as acquisition related amortization
charges, acquired in-process research and development relating to
license agreements and acquisitions, stock-based compensation
expense, foreign exchange gains or losses relating to translation
of foreign currency cash and investment balances and other
non-recurring items. Adjusted net loss from continuing operations,
adjusted net loss per share from continuing operations and adjusted
EBITDA also exclude litigation expenses related to defending
intellectual property claims. Revenue, as adjusted, excludes
non-recurring, non-operating revenue derived from license
agreements and other license revenue, net of license fees due to
licensors and excludes amounts accrued for costs incurred, and
potential future costs, related to our offer to accept returns of
Contour Threads brand product as part of our announced brand name
consolidation and discontinuation. Adjusted net loss from
continuing operations, adjusted net loss per share from continuing
operations, revenue, as adjusted, and adjusted EBITDA do not have
any standardized meaning prescribed by GAAP and therefore may not
be comparable to similar measures presented by other issuers.
Management uses these non-GAAP or adjusted operating measures to
establish operational goals, and believes that these measures may
assist investors in analyzing the underlying trends in our business
over time. Investors should consider these non-GAAP measures in
addition to, not as a substitute for, or as superior to, financial
reporting measures prepared in accordance with GAAP. We have
provided a reconciliation of these measures to GAAP in the attached
tables. The financial outlook referred to above presents certain
forward-looking, non-GAAP financial information for which at this
time there is no calculable comparable GAAP measure. As a result,
such non-GAAP financial information cannot be quantitatively
reconciled to comparable GAAP financial information. Specifically,
the estimates for certain operating expenses referred to above
exclude estimates of certain expenses that are inherently
unpredictable or subject to significant fluctuation for reasons
unrelated to our business performance, including stock-based
compensation expenses, certain litigation expenses and foreign
exchange gains or losses. Conference Call Information
--------------------------- A conference call to discuss these
financial results will be held today, Thursday, February 14, 2008
at 8:00 AM PT (11:00 AM ET). Dial-in information: North America
(toll free): (866) 510-0711 International: (617) 597-5379 Enter
passcode: 91184096 A replay archive of the conference call will be
available until February 21, 2008 by calling (888) 286-8010 (in
North America) or (617) 801-6888 (International) and entering
Access Code 85112963. A live webcast will be available to all
interested parties through the Investors section of Angiotech's
website: http://www.angiotech.com/. ANGIOTECH PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (in
thousands of U.S.$, except share and per Three months ended Three
months ended share data) December 31, 2007 December 31, 2006
-------------------------------------------------------------------------
Adjust- Adjust- Reported ments Adjusted Reported ments Adjusted
REVENUE Royalty revenue 27,158 27,158 47,475 (9,000)a 38,475
Product sales, net 43,935 (401)b 43,534 44,726 44,726 License fees
266 (266)c - 1,052 (1,052)c -
-------------------------------------------------------------------------
71,359 (667) 70,692 93,253 (10,052) 83,201
-------------------------------------------------------------------------
EXPENSES License and royalty fees 4,527 4,527 6,048 6,048 Cost of
products sold 24,158 (665)d 23,493 22,465 22,465 Research and
development 13,556 (150)e 13,406 12,165 (500)e 11,665 Selling,
general and administrative 27,180 (3,674)f 23,506 24,227 (6,229)f
17,998 Depreciation and amortization 8,826 (7,993)g 833 14,288
(13,316)g 972 In-process research and development 125 (125)h -
-------------------------------------------------------------------------
78,372 (12,607) 65,765 79,193 (20,045) 59,148
-------------------------------------------------------------------------
Operating (loss) income (7,013) 11,940 4,927 14,060 9,993 24,053
-------------------------------------------------------------------------
Other income (expenses): Foreign exchange gain (loss) 173 (173)i -
(1,263) 1,263 i - Investment and other income 511 155 n 666 1,028 4
n 1,032 Interest expense on long-term debt (12,774) 558 j (12,216)
(11,891) 699 j (11,192) Loss on redemption of investments - - - 126
(126)l - Loss on extinguish- ment of debt - - - (9,297) 9,297 m -
-------------------------------------------------------------------------
(12,090) 540 (11,550) (21,297) 11,137 (10,160)
-------------------------------------------------------------------------
Income (loss) from continuing operations before income taxes and
cumulative effect of change in accounting (19,103) 12,480 (6,623)
(7,237) 21,130 13,893 Income tax expense (recovery) (2,275) 3,149 k
874 (1,977) 3,880 k 1,903
-------------------------------------------------------------------------
Net (loss) income from continuing operations before cumulative
effect of change in accounting (16,828) 9,331 (7,497) (5,260)
17,250 11,990
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxes (4,448)
4,448 - (6,443) 6,443 -
-------------------------------------------------------------------------
Net (loss) income for the period (21,276) 13,779 (7,497) (11,703)
23,693 11,990
-------------------------------------------------------------------------
Basic net (loss) income per common share from continuing operations
(0.20) (0.09) (0.06) 0.14 Diluted net (loss) income per common
share from continuing operations (0.20) (0.09) (0.06) 0.14
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 85,030 85,030
84,984 84,984 Weighted average shares outstanding (000's) - diluted
85,030 85,030 85,547 85,547
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. One time revenue gain resulting from the up-front monetization
of a royalty revenue stream to be received from our collaboration
and distribution partnership with Orthovita. b. Amounts accrued for
costs incurred, and potential future costs, related to our offer to
accept returns of Contour Threads brand product as part of
consolidation and discontinuation of the Contour Threads brand
name, coincident with the launch of our Quill SRS brand name. c.
Non-recurring revenue relating to selected licence agreements, net
of licence fees due to licensors. d. Change in estimate of
accounting for excess and obsolete inventory resulting from the
alignment during the fourth quarter of 2007 of inventory policies
across our various manufacturing operations. e. Stock-based
compensation expense. f. Selling, general and administrative
adjustments:
---------------------------------------------------------------------
Three months Three months ended Dec. 30, ended Dec. 30, 2007 2006
----------------------------- Stock-based compensation expense
(439) (799) Termination and reorganization costs related to
facility consolidation and integration activities (3,526) (1,879)
Litigation expenses relating to defending intellectual property
claims 291 (3,551)
---------------------------------------------------------------------
(3,674) (6,229)
---------------------------------------------------------------------
g. Amortization of acquisition related intangible assets and
medical technologies. h. Non-recurring in-process research and
development relating to payments made to collaborators and
licensors, including to CombinatoRx Inc. and Rex Medical Inc., and
a non-recurring license termination payment of $125,000 to Lipose
Corporation made in October 2007. i. Foreign exchange fluctuations
on foreign currency net monetary assets. j. Amortization of
deferred financing costs. k. Tax effects of adjustments for the
period. Comparative for 2006 also includes non-recurring
retroactive tax adjustment of $8.7 million relating to certain tax
structures previously established in the province of Quebec, from
which the previously expected benefits are not anticipated to be
realized. l. Loss on redemption of investments. m. Loss on
extinguishment of the term loans related to our December 2006
senior floating rate note refinancing. n. Includes write off of AMI
tax receivable and write off of certain capitalized costs.
ANGIOTECH PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS
OF INCOME (Unaudited) (in thousands of U.S.$, except share and per
Year ended Year ended share data) December 31, 2007 December 31,
2006
-------------------------------------------------------------------------
Adjust- Adjust- Reported ments Adjusted Reported ments Adjusted
REVENUE Royalty revenue 116,659 116,659 175,254 (9,000)a 166,254
Product sales, net 170,193 2,579 b 172,772 138,590 138,590 License
fees 842 (842)c - 1,231 (1,231)c -
-------------------------------------------------------------------------
287,694 1,737 289,431 315,075 (10,231) 304,844
-------------------------------------------------------------------------
EXPENSES License and royalty fees 18,652 18,652 25,409 25,409 Cost
of products sold 95,529 (2,645)d 92,884 68,263 68,263 Research and
development 53,963 (4,582)e 49,381 45,393 (2,490)e 42,903 Selling,
general and administrative 99,713 (16,868)f 82,845 78,732 (17,262)f
61,470 Depreciation and amortization 33,429 (29,971)g 3,458 36,014
(32,707)g 3,307 In-process research and development 8,125 (8,125)h
- 1,042 (1,042)h -
-------------------------------------------------------------------------
309,411 (62,191) 247,220 254,853 (53,501) 201,352
-------------------------------------------------------------------------
Operating (loss) income (21,717) 63,928 42,211 60,222 43,270
103,492
-------------------------------------------------------------------------
Other income (expenses): Foreign exchange gain(loss) (341) 341 i -
515 (515)i - Investment and other income 10,393 (5,422)j 4,971
6,522 (829)k 5,693 Interest expense on long-term debt (51,748)
2,242 l (49,506) (35,502) 2,019 l (33,483) Loss on sale/write-down
of investments (8,157) 8,157 m - (287) 287 n - Loss extinguishment
of debt - - - (9,297) 9,297 o -
-------------------------------------------------------------------------
(49,853) 5,318 (44,535) (38,049) 10,259 (27,790)
-------------------------------------------------------------------------
Income (loss) from continuing operations before income taxes and
cumulative effect of change in accounting (71,570) 69,246 (2,324)
22,173 53,529 75,702 Income tax expense (recovery) (23,608) 17,589
p (6,019) 10,279 4,933 p 15,212
-------------------------------------------------------------------------
Income (loss) from continuing operations before cumulative effect
of change in accounting (47,962) 51,657 3,695 11,894 48,596 60,490
-------------------------------------------------------------------------
Net loss from discontinued operations, net of income taxe (11,395)
11,395 - (7,708) 7,708 -
-------------------------------------------------------------------------
Cumulative effect of change in accounting - - - 399 (399) -
-------------------------------------------------------------------------
Net (loss) income for the period (59,357) 63,052 3,695 4,585 55,905
60,490
-------------------------------------------------------------------------
Basic net (loss) income per common share from continuing operations
(0.56) 0.04 0.14 0.71 Diluted net (loss) income per common share
from continuing operations (0.56) 0.04 0.14 0.71
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average shares outstanding (000's) - basic 85,015 85,015
84,752 84,752 Weighted average shares outstanding (000's) - diluted
85,015 85,390 85,437 85,437
-------------------------------------------------------------------------
-------------------------------------------------------------------------
a. One time revenue gain resulting from the up-front monetization
of a royalty revenue stream to be received from our collaboration
and distribution partnership with Orthovita. b. Amounts accrued for
costs incurred, and potential future costs, related to our offer to
accept returns of Contour Threads brand product as part of
consolidation and discontinuation of the Contour Threads brand
name, coincident with the launch of our Quill SRS brand name. c.
Non-recurring, non-operating revenue as derived from license
agreements with Histogenics Corporation ($0.4 million in 2007),
Symphony Medical ($0.2 million in 2007) and other license revenue,
net of license fees due to licensors. In 2006, as derived from
license agreements with Baxter Heathcare Corporation ($1.0 million)
and other license revenue, net of license fees due to licensors. d.
Change in estimate of accounting for excess and obsolete inventory
resulting from the alignment during the third and fourth quarters
of 2007 of inventory policies across our various manufacturing
operations, and non-recurring supply / distribution agreement
termination costs. e. Research and development adjustments:
---------------------------------------------------------------------
Year ended Year ended Dec. 31, 2007 Dec. 31, 2006
------------------------------ Stock-based compensation (1,665)
(2,490) Non-recurring license fees due to licensors (419) -
Termination and reorganization costs related to the integration of
AMI (849) - Non-recurring supply / distribution agreement
termination costs (899) - Non-recurring in-process research and
development expense relating to the signing of a technology and
intellectual property license agreement (750) -
---------------------------------------------------------------------
(4,582) (2,490)
---------------------------------------------------------------------
f. Selling, general and administrative adjustments:
---------------------------------------------------------------------
Year ended Year ended Dec. 31, 2007 Dec. 31, 2006
------------------------------ Stock-based compensation (2,642)
(3,609) Termination and reorganization costs related to the
integration of AMI (8,365) (1,879) Litigation expenses relating to
defending intellectual property claims (5,611) (11,774)
Non-recurring supply / distribution agreement termination costs
(250) -
---------------------------------------------------------------------
(16,868) (17,262)
---------------------------------------------------------------------
g. Amortization of acquisition related intangible assets and
medical technologies. h. Non-recurring in-process research and
development expense relating to payments made to licensors and
collaborators, including CombinatorX Inc. and Rex Medical Inc. i.
Foreign exchange fluctuations on foreign currency net monetary
assets. j. Write off of uncollectible receivable and write off of
certain capitalized costs, net of gain realized on recovery of
investments. k. Gain on sale of Palo Alto building and gain on sale
related to disposition of Neodisc technology rights to NuVasive. l.
Amortization of deferred financing costs. m. Net impact of loss and
gain on redemption of investments of common share holdings in
Orthovita Inc. and NuVasive, Inc., respectively. n. Net impact of
gain on redemption of investments and loss on write down of
investments. o. Loss on extinguishment of term loans related to our
December 2006 senior floating rate note refinancing. p. Tax effects
of adjustments a. through n. for the period, including the reversal
of tax reserves previously booked. Comparative for 2006 also
includes non-recurring retroactive tax adjustment of $8.7 million
relating to certain tax structures previously established in the
province of Quebec, from which the previously expected benefits are
not anticipated to be realized. ANGIOTECH PHARMACEUTICALS, INC.
CALCULATION OF ADJUSTED EBITDA (Unaudited) Three months ended Year
ended December 31, December 31, (in thousands of U.S.$) 2007 2006
2007 2006
-------------------------------------------------------------------------
Net income on a GAAP basis (21,276) (11,703) (59,357) 4,585
Interest expense on long-term debt 12,774 11,891 51,748 35,502
Income tax expense 2,173 (5,619) (23,713) 6,247 Depreciation and
amortization 9,902 15,956 37,907 40,348
-------------------------------------------------------------------------
EBITDA 3,573 10,525 6,585 86,682
-------------------------------------------------------------------------
Adjustments: Net loss from discontinued operations, excluding
depreciation, amortization and income tax expense included above -
9,242 11,122 10,497 In-process research and development 125 - 8,125
1,042 Non-recurring research and development costs - - 750 -
Non-recurring revenue, net of license fees (266) (10,052) (426)
(10,231) Stock-based compensation 589 1,299 4,306 5,700 Litigation
expenses (291) 3,551 5,611 11,774 Foreign exchange loss (gain)
(173) 1,263 340 (515) Investment and other income (511) (1,032)
(4,814) (5,693) Severance / restructuring costs 3,526 1,879 8,964
1,879 Supply/distribution agreement termination costs - - 2,199 -
E&O inventory adjustment 665 - 2,645 - Loss on extinguishment
of debt - 9,297 - 9,297 Contour threads returns - - 2,579 -
Write-off of capitalized costs (401) - 280 - Write-off of
uncollectible tax receivable - - 2,250 - Gain on sale of sale of
intangible assets - - - (148) Gain on sale of Palo Alto building -
4 - (681) Gain realized on recovery of investment - - (7,510) -
Accrued interest income - - (597) - Net loss on redemption of
investments - (126) 8,157 287
-------------------------------------------------------------------------
Adjusted EBITDA 6,836 25,850 50,566 109,890
-------------------------------------------------------------------------
-------------------------------------------------------------------------
ANGIOTECH PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE
SHEETS (Unaudited) December 31, December 31, (in thousands of
U.S.$) 2007 2006
-------------------------------------------------------------------------
ASSETS Cash and short-term investments 91,326 108,617 Accounts
receivable 22,678 25,231 Inventories 33,647 33,619 Deferred income
taxes 5,964 5,372 Other current assets 7,070 6,303 Assets from
discontinued operations - 2,365
-------------------------------------------------------------------------
Total current assets 160,685 181,507
-------------------------------------------------------------------------
Long-term investments 24,456 53,840 Property and equipment, net
59,187 59,783 Intangible assets, net 225,889 244,954 Goodwill
660,591 630,770 Deferred income taxes - 4,804 Deferred financing
costs 13,600 14,845 Other assets 6,780 255 Assets from discontinued
operations - 15,116
-------------------------------------------------------------------------
Total assets 1,151,188 1,205,874
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities 67,182
67,950 Liabilities from discontinued operations - 4,226 Long-term
debt 575,000 575,000 Deferred income taxes 60,386 71,813 Other tax
liabilities 2,425 - Other long-term liabilities 4,614 4,052
Stockholders' equity 441,581 482,833
-------------------------------------------------------------------------
Total liabilities and stockholders' equity 1,151,188 1,205,874
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Forward Looking Statements -------------------------- Statements
contained in this press release that are not based on historical
fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions,
constitute "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995 and
constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities
legislation. Forward-looking statements may involve, but are not
limited to, comments with respect to our strategies or future
actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research
development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or
our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; adverse
results or unexpected delays in drug discovery and clinical
development processes; decisions, and the timing of decisions, made
by health regulatory agencies regarding approval of our technology
and products; the requirement for substantial funding to conduct
research and development and to expand commercialization activities
or consummate acquisitions; sales numbers and future guidance
publicly provided by Boston Scientific Corporation regarding sales
of their paclitaxel-eluting coronary stent products; and any other
factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual
results expressed or implied by the forward-looking statements in
this report to differ materially from our actual results. These
operating risks include: our ability to attract and retain
qualified personnel; our ability to successfully complete
preclinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the ability of Boston
Scientific Corporation to successfully manufacture, market and sell
their paclitaxel-eluting coronary stent products; the continued
availability of capital to finance our activities; our ability to
achieve the financial benefits expected as a result of the
acquisition of American Medical Instruments Holdings, Inc. ("AMI");
and any other factors referenced in our annual information form and
other filings with the applicable Canadian securities regulatory
authorities or the SEC. Given these uncertainties, assumptions and
risk factors, readers are cautioned not to place undue reliance on
such forward-looking statements. We disclaim any obligation to
update any such factors or to publicly announce the result of any
revisions to any of the forward-looking statements contained in
this press release to reflect future results, events or
developments. Quill(TM) is a trademark of Quill Medical, Inc., a
wholly-owned subsidiary of Angiotech Pharmaceuticals, Inc. (C)2008
Angiotech Pharmaceuticals, Inc. All Rights Reserved. Vascular
Wrap(TM) is a trademark of Angiotech Pharmaceuticals, Inc.
BioPince(TM) is a trademark of Medical Device Technologies, Inc.
Skater(TM) is a trademark of PBN MEDICALS DENMARK A/S. MultiStem(R)
is a registered trademark of Athersys, Inc. TAXUS(R) is a
registered trademark of Boston Scientific Corporation. About
Angiotech Pharmaceuticals Angiotech Pharmaceuticals, Inc. is a
global specialty pharmaceutical and medical device company with
over 1,500 dedicated employees. Angiotech discovers, develops and
markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical
interventions and acute injury. To find out more about Angiotech
(NASDAQ:ANPINASDAQ:TSXNASDAQ:ANP) please visit our website at
http://www.angiotech.com/. CONTACT: Jodi Regts, Senior Manager,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 221-7930, ; Deirdre Neary, Manager,
Investor Relations and Corporate Communications, Angiotech
Pharmaceuticals, Inc., (604) 222-7056 DATASOURCE: Angiotech
Pharmaceuticals, Inc. CONTACT: Jodi Regts, Senior Manager, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (604) 221-7930, ; Deirdre Neary, Manager, Investor Relations
and Corporate Communications, Angiotech Pharmaceuticals, Inc.,
(604) 222-7056
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024